Naegeli Hanspeter, Birch Andrew Nicholas, Casacuberta Josep, De Schrijver Adinda, Gralak Mikolaj Antoni, Guerche Philippe, Jones Huw, Manachini Barbara, Messéan Antoine, Nielsen Elsa Ebbesen, Nogué Fabien, Robaglia Christophe, Rostoks Nils, Sweet Jeremy, Tebbe Christoph, Visioli Francesco, Wal Jean-Michel, Paraskevopoulos Konstantinos
EFSA J. 2017 Mar 24;15(3):e04745. doi: 10.2903/j.efsa.2017.4745. eCollection 2017 Mar.
The EFSA Panel on Genetically Modified Organisms (GMO) has previously assessed the single events Bt11, MIR162, MIR604 and GA21 as well as different stacked events corresponding to combinations of these events. These maize events were found to be as safe as their conventional counterparts and other appropriate comparators with respect to potential effects on human and animal health and the environment. In its assessment of the four-event maize stack Bt11 × MIR162 × MIR604 × GA21, the GMO Panel also assessed all the subcombinations of these events not previously assessed, including some for which little or no experimental data were provided, including the two-stack maize event Bt11 × MIR162 (application EFSA-GMO-DE-2009-66). On 8 November 2016, the European Commission received from Syngenta information on the subcombination Bt11 × MIR162. On 14 December 2016, the European Commission tasked EFSA to analyse these data and to indicate whether they have an impact on the previously issued opinion on the four-event stack Bt11 × MIR162 × MIR604 × GA21 and its subcombinations. The GMO Panel used the appropriate principles described in its guidelines for the risk assessment of genetically modified (GM) plants to analyse the provided data. The levels of the newly expressed proteins Cry1Ab, PAT, Vip3Aa20 and PMI are similar between the two-event stack Bt11 × MIR162 and the corresponding single events Bt11 and MIR162. Based on this analysis, there is no indication of an interaction between the events combined in maize Bt11 × MIR162 that would affect the levels of the newly expressed proteins. Thus, the GMO Panel considers that the new information for maize Bt11 × MIR162 does not alter the conclusions of the scientific opinion on application EFSA-GMO-DE-2009-66.
欧洲食品安全局转基因生物小组先前已对单一事件Bt11、MIR162、MIR604和GA21以及与这些事件组合相对应的不同复合事件进行了评估。就对人类和动物健康以及环境的潜在影响而言,这些玉米事件被认为与其传统对应物和其他合适的对照物一样安全。在对四事件玉米组合Bt11×MIR162×MIR604×GA21进行评估时,转基因生物小组还评估了这些事件以前未评估过的所有子组合,包括一些提供的实验数据很少或没有实验数据的子组合,包括双事件玉米事件Bt11×MIR162(申请编号EFSA - GMO - DE - 2009 - 66)。2016年11月8日,欧盟委员会收到了先正达公司提供的关于Bt11×MIR162子组合的信息。2016年12月14日,欧盟委员会责成欧洲食品安全局分析这些数据,并指出它们是否会对先前发布的关于四事件组合Bt11×MIR162×MIR604×GA21及其子组合的意见产生影响。转基因生物小组采用了其转基因植物风险评估指南中描述的适当原则来分析所提供的数据。双事件组合Bt11×MIR162与相应的单一事件Bt11和MIR162之间新表达的Cry1Ab、PAT、Vip3Aa20和PMI蛋白水平相似。基于这一分析,没有迹象表明玉米Bt11×MIR162中组合的事件之间存在相互作用会影响新表达蛋白的水平。因此,转基因生物小组认为,玉米Bt11×MIR162的新信息不会改变关于申请编号EFSA - GMO - DE - 2009 - 66的科学意见的结论。